Cerebrolysin

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Cerebrolysin is not approved by the FDA for any indication. It is not listed on the FDA 503A bulk drug substances list and is not eligible for compounding under current US law. Unlike some other peptides affected by the 2026 FDA Category 2 reclassification process, cerebrolysin is not on the Section 503A Category 2 list (which applies specifically to nominated small-molecule and synthetic peptide candidates); it is simply not an FDA-authorized preparation. It cannot be legally sold, compounded, or dispensed for human use in the United States outside of a registered clinical trial.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Cerebrolysin

Origin

Cerebrolysin is a standardized injectable preparation obtained by enzymatic proteolysis of purified porcine brain cortex tissue. The resulting hydrolysate consists of low-molecular-weight neuropeptides (all below ~10 kDa) and free amino acids. Because it is a complex biological mixture with no single defined sequence or CAS number, it has no PubChem CID or InChIKey; it is identity-confirmed by biological standardization and amino acid profile. The preparation is manufactured by EVER Neuro Pharma (Austria) and is approved in over 50 countries for neurological indications, though it has not received FDA approval in the United States.

Appearance

Clear, amber-colored sterile solution for injection (aqueous)

Solubility

Supplied as a ready-to-use aqueous solution; lyophilized powder formulations are…

Sequence not available in current seed.

Stability: As a biological peptide mixture, cerebrolysin is sensitive to heat, UV light, and repeated freeze-thaw cycles. Opened ampoules should be used immediately. Forma

Vial sizes

null mg

Purity grades

pharmaceutical-grade (approved markets) / research-grade (RUO supply)

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Cerebrolysin's peptide components are small enough to cross the blood-brain barrier and act through multiple convergent pathways
• Several constituent peptides structurally and functionally resemble endogenous neurotrophins including BDNF, NGF, GDNF, and CNTF, engaging Trk receptor families (TrkA, TrkB) and activating downstream MAPK/ERK, PI3K/Akt, and PLCγ signaling cascades
• This receptor-mediated signaling promotes dendritic spine formation, synaptic protein synthesis, and suppression of apoptotic cascades
• Concurrently, cerebrolysin reduces microglial hyperactivation and attenuates neuroinflammatory signaling, an effect observed in both in vivo rodent models and primary cell cultures

Pharmacokinetics (ADME)

Half-life

Approximately 2.5–3.5 hours (IV bolus); approximately 4.5–6 hours apparent half-life (IM depot absorption included). Note: these figures are reported in manufacturer pharmacological summaries and vendor-cited pharmacology documents; formal peer-reviewed PK publications are sparse for the mixture as a whole.

Clearance

Constituent peptides are cleared via proteolytic degradation to amino acids and renal elimination; formal clearance values for the mixture are not published in indexed literature

PK–PD note: Despite relatively short plasma half-lives, downstream neurotrophic signaling effects in animal and clinical models are reported to persist for 48–72 hours post-dose, attributed to receptor-mediated a…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Patel PN et al. Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 RCTs. Cureus. 2025;17(8):e91054. — 14 RCTs, N=2884; NIHSS MD +1.39 (95% CI 0.53-2.25, p=0.020); functional independence non-significant trend.
• Ziganshina LE et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2017;(4):CD007026. — 6 RCTs, 1501 participants; no demonstrated clinical benefit; increased non-fatal SAEs (RR 2.47, 95% CI 1.09-5.58).
• Ziganshina LE et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;CD008900. — 6 RCTs, 597 participants; modest cognitive benefit (SMD 0.36, 95% CI 0.13-0.58, very low-quality evidence); not recommended for routine use.
• Muresanu DF et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine RCTs. 2018. — 9 ischemic stroke RCTs; global neurological improvement during early post-stroke period.
• Xiong W et al. Effects of cerebrolysin on functional outcome of patients with TBI: a systematic review and meta-analysis.
• Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: Systematic Review and Meta-Analysis of Twelve RCTs. Pharmaceuticals. 2021;14(12):1297.

5 registered trials — 1 currently recruiting.

Phase 4
NCT00868283
The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke

COMPLETED

—
NCT01556854
Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke

UNKNOWN

Phase 1
NCT05821075
Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy

RECRUITING

Phase 2
NCT04751136
the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome

COMPLETED

NA
NCT06070753
A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)

UNKNOWN

Summary (literature)

A systematic review and meta-analysis pooling over 2,200 patients from 12 stroke RCTs (MDPI Pharmaceuticals 2021, PMC8708612) found no statistically significant differences between cerebrolysin and placebo in serious adverse events, mortality, or hemorrhagic transformation rates.…

WADA status

Not specifically listed by name on the WADA 2026 Prohibited List. However, individual constituent peptides or growth factor-mimicking activities could potential…

Dominant research route: Intravenous (IV) infusion

Adult patients with acute ischemic stroke, TBI, and dementia (human); administered as IV infusion diluted in saline over 15–60 min in RCTs

Bioavailability: Parenteral route bypasses GI degradation; IV infusion is the most-studied administration in published RCTs (e.g., CASTA trial used 30 mL/day IV for 10 days). Conventional pharmacokinetic analysis of individual peptide components is not feasible per the manufacturer due to the complex oligopeptide mixture.

Dominant research route. A 2025 systematic review/meta-analysis of 14 RCTs restricted inclusion to trials evaluating intravenous Cerebrolysin in adult acute ischemic stroke patients. The CASTA double-blind RCT administered 30 mL Cerebrolysin daily as IV infusion for 10 days. The Alzheimer's Drug Discovery Foundation notes clinical studies used 30 mL/day IV for 4 weeks.

Adult post-stroke rehabilitation patients (human); IM injection into deltoid/quadriceps/gluteus once daily

Bioavailability: Parenteral route; manufacturer's treatment handbook indicates IM injections into different muscles or at different times may be given. A retrospective controlled study administered 10 mL Cerebrolysin IM daily for 30 days in post-stroke spasticity rehabilitation.

Studied in a retrospective controlled monocentric study (n=23 treated) of post-stroke spasticity; IM treatment for 30 days was reported safe and well tolerated. The official Cerebrolysin Treatment Handbook lists IM as an accepted route alongside IV.

Elderly control subjects (human); single uncontrolled trial of oral Cerebrolysin assessing EEG alpha activity and cognitive performance

Bioavailability: Peptide fractions are expected to be degraded by gastric acid and pancreatic proteases in the GI tract; the Alzheimer's Drug Discovery Foundation states peptides like those in Cerebrolysin are typically broken down in the gut without reaching the body or brain, hence the drug is given by injection. One small uncontrolled 2000 trial (Alvarez et al.) reported oral Cerebrolysin enhanced brain alpha activity in elderly controls, but this is not the studied standard route.

Oral route is not the approved/studied standard; only a single small uncontrolled trial (Alvarez XA et al., J Neural Transm Suppl 2000) has examined oral administration in elderly control subjects. Oral-stability concern: peptide hydrolysate susceptible to GI enzymatic degradation; not established as systemically bioavailable.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $0.170 · median $0.830 · p75 $1.05 · 7 researched vendors

Legit, COA-backed band: $0.170–$1.65/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$0

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Research-grade peptide vendors advertise ≥99% purity by HPLC for synthetic Cerebrolysin; no independent third-party lab purity range for the authentic pharmaceutical product (Ever Neuro Pharma) was located in public databases. Manufacturer-stated composition is a standardized porcine brain-derived peptide preparation (~25% low-molecular-weight peptides <1 kDa, ~75% free amino acids).

Independent labs cited for this compound

No Cerebrolysin-branded manufacturer recall found. The only recall event identified is the 2020-2021 voluntary recall of all compounded sterile products (including Cerebrolysin-containing preparations) by The Guyer Institute / Advanced Nutriceuticals LLC due to lack of sterility assurance, per FDA Warning Letter 615908.

Buyer red-flag checklist

• Cerebrolysin is not FDA-approved and is not legally marketed in the United States; importation is subject to FDA Import Alert 66-41 (DWPE of unapproved new drugs).
• FDA Warning Letter 615908 (2021) explicitly named Cerebrolysin as a bulk drug substance not on the 503A bulks list, rendering compounded preparations ineligible for compounding exemptions.
• FDA Orphan Drug Designation for frontotemporal dementia (2016) was subsequently withdrawn/revoked; no FDA approval for any indication.
• Community reports of counterfeit Cerebrolysin ampoules with inconsistent packaging and ampoule characteristics from online suppliers (de-identified aggregate; no individual user attribution).
• Authentic pharmaceutical Cerebrolysin (Ever Neuro Pharma) is a porcine brain-derived biological mixture, not a single synthetic peptide — purity verification methods differ from standard synthetic peptide HPLC testing.
• No independent third-party lab test results (Janoshik, MZ Biolabs, etc.) for Cerebrolysin were located in public databases, limiting verifiable purity/underdosing assessment.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent lab tests (Janoshik Analytical, MZ Biolabs, Finnrick, or equivalent) specific to Cerebrolysin were located in public repositories. Underdosing prevalence cannot be quantified from available evidence.

• Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. Cerebrolysin is not FDA-approved and is not legally marketed in the United States; as an unapproved new drug it falls within the scope of this import alert. Cerebrolysin was not found explicitly named on the public Red List of IA 66-41, but the alert applies to unapproved new drug products generally.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Not prohibited. Cerebrolysin is not currently listed as banned under the WADA Prohibited List, either directly or via similarity. Not listed under any explicit class in the 2026 Prohibited List.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-experimentation / self-medication
• Grey-market self-sourcing from unverified vendors
• Influencer promotion (Leo and Longevity, deceased)
• Survivorship bias in positive self-report threads
• Expectation / placebo effects in unblinded self-trials
• Sourcing-vendor commercial interest

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Porcine brain-derived peptide mixture studied in stroke, TBI, and dementia for neurotrophic and neuroprotective effects in 40+ registered clinical trials. Approximately 658 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Not FDA-approved; no compounding pathway; Research Use Only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet